摘要:
Clostridium difficile is one of the most common causes of health-care acquired diarrhoea, resulting in a spectrum of disease from mild diarrhoea to life-threatening illness. Particular human Lactobacillus strains, including Lactobacillus gasseri APC678, are described as useful therapeutic agents to target C. difficile colonisation or infection.
摘要:
An isolated lantibiotic is provided comprising amino acid sequence SEQ. ID No. 2 and at least one of amino acid sequences SEQ. ID No. 4 and SEQ. ID. No 6. Also provided is use of the lantibiotic in the treatment or prevention of infection by Group B Streptococcus or Corynebacterium xerosis. The invention further relates to isolated S. hominis strains and use of same in producing the lantibiotic. A vector is provided comprising nucleotides sequences for producing the lantibiotic.
摘要:
The present invention relates to a new bacteriocin, to microbial strains which can produce it and to uses of the bacteriocin and the strains. The bacteriocin is effective against Clostridium difficile and Listeria monocytogenes amongst other organisms.
摘要:
An antimicrobial which is effective against a range of Gram positive organisms is described. The antimicrobial is the bacteriocin lacticin 3147, which is shown to be effective both in vivo and in vitro against a range of Gram positive organisms.
摘要:
The present invention relates to a nisin derivative comprising amino acid substitutions in the peptide sequence encoding the hinge region of the protein, wherein the derivative exhibits an increased anti-microbial activity.
摘要:
The invention relates to a variant nisin peptide, wherein the variant nisin peptide is a modified variant of wild-type nisin, wherein the modification comprises or consists of an amino acid residue modification selected from: i) M17Q or M17A; ii) T2L; and iii) one set of modified hinge residues selected from a) N20H and M21T, b) N20V, M21G, and K22A, c) N20V, M21G, and K22V or d) N20V, M21G, and K22T; or v) combinations of modifications i), ii), and iii), and related medical uses and products comprising such nisin peptides.
摘要:
The production of a spray-dried bacteriocin lacticin 3147 powder is described. The powder is shown to have effective anti-microbial activity in a range of foodstuffs, namely infant milk formulations, powdered soup, yoghurt and cottage cheese. Increased anti-microbial activity was demonstrated when the lacticin 3147 powder was used in conjunction with increased hydrostatic pressure. The process comprises: inoculating a medium with a lacticin 3147-producing strain of bacteria, fermenting the inoculated medium, adjusting the pH of the fermentation to 6.3-6.7, inactivating the bacterial fermentate and evaporating the fermentate.